Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 171

Results For "bio"

4179 News Found

Surya Brasil eyes India expansion after 30% US growth
News | February 23, 2026

Surya Brasil eyes India expansion after 30% US growth

The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner


Merck restructures Human Health division for future growth
News | February 23, 2026

Merck restructures Human Health division for future growth

Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential


Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial
Clinical Trials | February 22, 2026

Lilly’s Retevmo shows breakthrough results in early-stage lung cancer trial

The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns


Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill
News | February 21, 2026

Zeus Hygia and Patch House Labs join forces to take nutraceuticals beyond the pill

The agreement will see the two companies jointly develop and commercialise premium nutraceutical ingredients in advanced transdermal delivery formats


Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
News | February 19, 2026

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar


Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI
R&D | February 18, 2026

Evogene and QUT join forces to tackle chemotherapy-resistant lung cancer with AI

Dr Adams’ lab recently uncovered a novel cellular detoxification pathway driving Cisplatin resistance in NSCLC


Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program
Biopharma | February 18, 2026

Newron Pharmaceuticals bags up to €38 million to fuel Phase III ENIGMA-TRS program

A final tranche of €12 million will follow, contingent on positive pivotal study results, with the share price calculated according to an agreed formula